Presented at #ASCO24:
Among patients who received two 3-week cycles of neoadjuvant ipilimumab and nivolumab, the 12-month event-free survival was 83.7%, as compared with 57.2% among those who received only adjuvant therapy. Full NADINA trial results: https://t.co/ZxWxo2qgNy
Talking about updates in the world of melanoma at MOASC summit in NB tomorrow! @MOASC_Office
I’ll be talking about exciting updates in world of melanoma treatment and novel therapeutics in research @angelesclinic with @Mi_onc@OmidHamidMD @CSCancerCenter !
Just published by @ASCO#TAPUR. Olaparib in Patients With Pancreatic Cancer With BRCA1/2 Mutations: Results From the Targeted Agent and Profiling Utilization Registry Study | JCO Precision Oncology https://t.co/P4BvB7XB6J
Regorafenib in Patients With Solid Tumors With BRAF Alterations: Results From the Targeted Agent and Profiling Utilization Registry (TAPUR) Study | JCO Precision Oncology @ASCO@rschilsky@JCOPO_ASCO@OncoAlert
https://t.co/LZuogm4S6Y